Literature DB >> 17509992

Urine cytology discrepancies: frequency, causes, and outcomes.

Stephen S Raab1, Dana Marie Grzybicki, Colleen M Vrbin, Kim R Geisinger.   

Abstract

Although urine cytology is used for the early detection and surveillance of urothelial carcinoma, there has been little study of the frequency, causes, and outcomes of cytologic-histologic discrepancies. We obtained histologic follow-up in 361 (6.2%) of 5,785 voided, 124 (19.5%) of 636 lower tract instrumented, and 23 (33%) of 69 upper tract urinary cytologic specimens from 1 institution during a 2-year timeframe to determine diagnostic discrepancy frequency and outcomes. Cytologic-histologic discrepancies were observed in 208 (40.9%) cases with histologic followup, and the cause of discrepancy was interpretation and sampling in 35.1% and 63.0%, respectively. Of all discrepancies, 101 (48.6%) resulted in minimal or mild harm, consisting mainly of repeated testing and/or diagnostic delays. Severe harm never was observed. We conclude that current screening and surveillance methods that incorporate urine cytology are accurate in diagnosing urothelial cancer. However, the current protocols result in potentially reducible errors that lead to unnecessary testing and diagnostic delays.

Entities:  

Mesh:

Year:  2007        PMID: 17509992     DOI: 10.1309/XUVXFXMFPL7TELCE

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  16 in total

1.  Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy.

Authors:  Philip H Kim; Ranjit Sukhu; Billy H Cordon; John P Sfakianos; Daniel D Sjoberg; A Ari Hakimi; Guido Dalbagni; Oscar Lin; Harry W Herr
Journal:  BJU Int       Date:  2014-02-14       Impact factor: 5.588

2.  Effect of contrast media on urinary cytopathology specimens.

Authors:  Sebastian Frees; Samir Bidnur; Michael Metcalfe; Peter Raven; Claudia Chavez-Munoz; Igor Moskalev; Ladan Fazli; Alan So
Journal:  Can Urol Assoc J       Date:  2016-08       Impact factor: 1.862

3.  Quantitative phase imaging to improve the diagnostic accuracy of urine cytology.

Authors:  Hoa V Pham; Liron Pantanowitz; Yang Liu
Journal:  Cancer Cytopathol       Date:  2016-05-13       Impact factor: 5.284

4.  Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology.

Authors:  Anobel Y Odisho; Anna B Berry; Ardalan E Ahmad; Matthew R Cooperberg; Peter R Carroll; Badrinath R Konety
Journal:  Eur Urol       Date:  2012-04-14       Impact factor: 20.096

5.  Diagnostic significance of atypical category in the voided urine samples: A retrospective study in a tertiary care center.

Authors:  Ghadeer A Mokhtar; Mohamed Al-Dousari; Doaa Al-Ghamedi
Journal:  Urol Ann       Date:  2010-09

6.  APE1/Ref-1 as a Serological Biomarker for the Detection of Bladder Cancer.

Authors:  Ju Hyun Shin; Sunga Choi; Yu Ran Lee; Myoung Soo Park; Yong Gil Na; Kaikobad Irani; Sang Do Lee; Jin Bong Park; Jin Man Kim; Jae Sung Lim; Byeong Hwa Jeon
Journal:  Cancer Res Treat       Date:  2015-01-02       Impact factor: 4.679

7.  Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development.

Authors:  Maria Frantzi; Akshay Bhat; Agnieszka Latosinska
Journal:  Clin Transl Med       Date:  2014-03-29

8.  Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.

Authors:  Karolina Boman; Ulrika Segersten; Göran Ahlgren; Jakob Eberhard; Mathias Uhlén; Karin Jirström; Per-Uno Malmström
Journal:  BMC Urol       Date:  2013-04-08       Impact factor: 2.264

9.  Evaluation of a triple combination of cytokeratin 20, p53 and CD44 for improving detection of urothelial carcinoma in urine cytology specimens.

Authors:  Brent Arville; Emily O'Rourke; Fai Chung; Mahul Amin; Shikha Bose
Journal:  Cytojournal       Date:  2013-12-27       Impact factor: 2.091

10.  Photodynamic diagnosis - current tool in diagnosis of carcinoma in situ of the urinary bladder.

Authors:  Marek Ireneusz Lipiński; Waldemar Różański; Michał Paweł Markowski
Journal:  Contemp Oncol (Pozn)       Date:  2015-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.